WallStreetZenWallStreetZen

NYSE: BIO
Bio Rad Laboratories Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for BIO

Based on 2 analysts offering 12 month price targets for Bio Rad Laboratories Inc.
Min Forecast
$700.00+67.81%
Avg Forecast
$707.50+69.61%
Max Forecast
$715.00+71.41%

Should I buy or sell BIO stock?

Based on 2 analysts offering ratings for Bio Rad Laboratories Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BIO stock forecasts and price targets.

BIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Credit Suisse
Top 8%
93
BuyInitiates Coverage On$715.00+71.41%2022-08-25
Citigroup
Top 5%
96
Strong BuyMaintains$700.00+67.81%2022-07-08

1 of 1

Forecast return on equity

Is BIO forecast to generate an efficient return?
Company
5.95%
Industry
19.48%
Market
110.02%
BIO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BIO forecast to generate an efficient return on assets?
Company
4.18%
Industry
10.82%
BIO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BIO earnings per share forecast

What is BIO's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$14.35
Avg 2 year Forecast
$15.65
Avg 3 year Forecast
$17.87

BIO revenue forecast

What is BIO's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$2.9B-0.7%
Avg 2 year Forecast
$3.1B+6.71%
Avg 3 year Forecast
$3.3B+15.08%
BIO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BIO revenue growth forecast

How is BIO forecast to perform vs Medical Devices companies and vs the US market?
Company
3.46%
Industry
4.69%
Market
8.53%
BIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BIO vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
BIO$417.14$707.50+69.61%Strong Buy
ABMD$245.66$311.25+26.70%Hold
SNN$23.22$34.50+48.58%Buy
SWAV$278.07$240.50-13.51%Buy
PODD$229.40$279.82+21.98%Buy

Bio Rad Laboratories Stock Forecast FAQ

Is Bio Rad Laboratories Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSE: BIO) stock is to Strong Buy BIO stock.

Out of 2 analysts, 1 (50%) are recommending BIO as a Strong Buy, 1 (50%) are recommending BIO as a Buy, 0 (0%) are recommending BIO as a Hold, 0 (0%) are recommending BIO as a Sell, and 0 (0%) are recommending BIO as a Strong Sell.

If you're new to stock investing, here's how to buy Bio Rad Laboratories stock.

What is BIO's earnings growth forecast for 2022-2024?

(NYSE: BIO) Bio Rad Laboratories's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 26.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.13%.

Bio Rad Laboratories's earnings in 2022 is -$1,942,423,000.On average, 2 Wall Street analysts forecast BIO's earnings for 2022 to be $426,160,316, with the lowest BIO earnings forecast at $426,160,316, and the highest BIO earnings forecast at $426,160,316. On average, 2 Wall Street analysts forecast BIO's earnings for 2023 to be $464,767,174, with the lowest BIO earnings forecast at $464,470,198, and the highest BIO earnings forecast at $464,767,174.

In 2024, BIO is forecast to generate $530,695,808 in earnings, with the lowest earnings forecast at $530,695,808 and the highest earnings forecast at $530,695,808.

What is BIO's revenue growth forecast for 2022-2024?

(NYSE: BIO) Bio Rad Laboratories's forecast annual revenue growth rate of 3.46% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 4.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.53%.

Bio Rad Laboratories's revenue in 2022 is $2,870,979,000.On average, 2 Wall Street analysts forecast BIO's revenue for 2022 to be $84,667,660,645, with the lowest BIO revenue forecast at $84,513,381,701, and the highest BIO revenue forecast at $84,821,939,589. On average, 2 Wall Street analysts forecast BIO's revenue for 2023 to be $90,981,218,303, with the lowest BIO revenue forecast at $90,853,815,672, and the highest BIO revenue forecast at $91,108,620,934.

In 2024, BIO is forecast to generate $98,119,477,841 in revenue, with the lowest revenue forecast at $98,114,874,715 and the highest revenue forecast at $98,124,080,966.

What is BIO's forecast return on assets (ROA) for 2022-2024?

(NYSE: BIO) forecast ROA is 4.18%, which is lower than the forecast US Medical Devices industry average of 10.82%.

What is BIO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BIO price target, the average BIO price target is $707.50, with the highest BIO stock price forecast at $715.00 and the lowest BIO stock price forecast at $700.00.

On average, Wall Street analysts predict that Bio Rad Laboratories's share price could reach $707.50 by Aug 25, 2023. The average Bio Rad Laboratories stock price prediction forecasts a potential upside of 69.61% from the current BIO share price of $417.14.

What is BIO's Earnings Per Share (EPS) forecast for 2022-2024?

(NYSE: BIO) Bio Rad Laboratories's current Earnings Per Share (EPS) is -$64.90. On average, analysts forecast that BIO's EPS will be $14.35 for 2022, with the lowest EPS forecast at $14.35, and the highest EPS forecast at $14.35. On average, analysts forecast that BIO's EPS will be $15.65 for 2023, with the lowest EPS forecast at $15.64, and the highest EPS forecast at $15.65. In 2024, BIO's EPS is forecast to hit $17.87 (min: $17.87, max: $17.87).

What is BIO's forecast return on equity (ROE) for 2022-2024?

(NYSE: BIO) forecast ROE is 5.95%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.